A startup offered a reporter unproven rejuvenation injections.
Generation Lab won’t disclose the drugs, making its safety and dosing impossible to verify.
Aging is not a registrable drug indication, so longevity products cannot go through a formal approval trial.
Its planned trial will charge participants to enroll, a model researchers call pay-to-play.
Sources: MIT Technology Review